{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:01:10Z","timestamp":1760238070561,"version":"build-2065373602"},"reference-count":10,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatopathology"],"abstract":"<jats:p>Auto-immune reactions, including auto-immune bullous disease, have been reported following SARS-CoV-2 virus vaccination. Few cases of bullous pemphigoid are described, but there has been no case of pemphigoid gestationis. We report the first case here.<\/jats:p>","DOI":"10.3390\/dermatopathology9030025","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T22:43:00Z","timestamp":1656024180000},"page":"203-206","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pseudo-Pemphigoid Gestationis Eruption Following SARS-CoV-2 Vaccination with mRNA Vaccine"],"prefix":"10.3390","volume":"9","author":[{"given":"Caroline","family":"de Lorenzi","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-549X","authenticated-orcid":false,"given":"G\u00fcrkan","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland"},{"name":"Department of Clinical Pathology, Geneva University Hospitals, CH-1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8087-1161","authenticated-orcid":false,"given":"Laurence","family":"Toutous Trellu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cup.14104","article-title":"Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination","volume":"49","author":"Larson","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jiph.2021.06.021","article-title":"Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report","volume":"14","author":"Kong","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_4","first-page":"e257","article-title":"Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review","volume":"36","author":"Pauluzzi","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"149","author":"Agharbi","year":"2021","journal-title":"Annal. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"807711","DOI":"10.3389\/fmed.2021.807711","article-title":"Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React with Pemphigus or Pemphigoid Autoantigens","volume":"8","author":"Kasperkiewicz","year":"2021","journal-title":"Front. Med."},{"key":"ref_7","first-page":"e23127","article-title":"Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases","volume":"14","author":"Hali","year":"2022","journal-title":"Cureus"},{"key":"ref_8","first-page":"e412","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.15679","article-title":"Review of autoimmune blistering diseases: The Pemphigoid diseases","volume":"33","author":"Daniel","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jamadermatol.2021.5294","article-title":"Autoreactivity to BP180 Neoepitopes in Patients with Pemphigoid Gestationis","volume":"158","author":"Schauer","year":"2022","journal-title":"JAMA Dermatol."}],"container-title":["Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2296-3529\/9\/3\/25\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:01Z","timestamp":1760139541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2296-3529\/9\/3\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":10,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["dermatopathology9030025"],"URL":"https:\/\/doi.org\/10.3390\/dermatopathology9030025","relation":{},"ISSN":["2296-3529"],"issn-type":[{"type":"electronic","value":"2296-3529"}],"subject":[],"published":{"date-parts":[[2022,6,24]]}}}